• BG Medicine Inc., of Waltham, Mass., said results of a research study conducted at the Massachusetts General Hospital provided additional evidence that elevated levels of galectin-3 predict adverse outcomes in chronic heart failure and suggested the prognostic value of the noninvasive biomarker may be enhanced when serial measurements are made over time.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST